Soyoung Lim

TL;DR: The data indicate that LSD1 may provide a predictive marker for aggressive biology and a novel attractive therapeutic target for treatment of ER-negative breast cancers.

TL;DR: First evidence that a histone demethylase, LSD1, is involved in maintaining the undifferentiated, malignant phenotype of neuroblastoma cells is provided, showing that inhibition of LSD1 reprograms the transcriptome of neuro Blastoma cells and inhibits Neuroblastoma xenograft growth in vivo.

TL;DR: Namoline, a γ‐pyrone, is identified as a novel, selective and reversible LSD1 inhibitor, which leads to silencing of AR‐regulated gene expression and severely impairs androgen‐dependent proliferation in vitro and in vivo.

TL;DR: The observation that overexpression, amplification or mutations of several histone demethylases have been found in many types of tumors, raise the possibility of using these enzymes as diagnostic tools as well as pave a way for the discovery of novel therapeutic targets and treatment modalities.

TL;DR: TFAP2a was strongly expressed in 4 of 6 neuroblastoma cell lines tested, and TFAP2A siRNA mediated knock down in SH-EP cells reduced proliferation and induced a more differentiated phenotype associated with an increase in the expression of the differentiation marker neurotensin.